BiotechTV - News cover image

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

BiotechTV - News

00:00

Avoiding Thrombocytopenia Through Differentiated Safety

Stefanie Fluckiger-Mangual says earlier CBP inhibitors were limited by thrombocytopenia, while TT125-802 showed no cases among 45 patients.

Play episode from 02:39
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app